Investor Presentaiton
ersonal use only
6
Future acceleration in lab rollout plans underpinned by strong pipeline
9 sites with
agreements to
purchase
Imricor's
Nine clinical sites now contracted across Germany, The Netherlands & France
•
Dresden Heart Centre, Germany, a training Centre of Excellence;
.
Haga Hospital, The Netherlands;
•
.
•
Amsterdam University Medical Centre, The Netherlands;
Leipzig Heart Centre, Germany, a training Centre of Excellence;
Rhön Clinic Bad Neustadt Campus, Germany;
Maastricht University Medical Centre, The Netherlands;
products
•
South Paris Cardiovascular Institute, France; and
.
Lübeck University Heart Centre, UKSH, Germany.
•
Münster University Hospital, Germany
Initial sites (e.g. Dresden, Leipzig) are set up as training Centres of Excellence for sites that follow
•
•
Strong pipeline
•
•
•
Discussions well advanced across a number of sites, many at final stage of review and
execution
Strong and growing pipeline of potential sites supported by increasing awareness and
education of Imricor's product
Agreement with Sana GPO provides access to ~80 sites for sales & marketing
Further enhanced by Philips sales distribution agreement and collaborative relationship
with Siemens to drive lab adoption.
A well-developed longer-term pipeline aligned with capital cycles of clinical sites
Expecting to recommence signing new agreements during the second quarter,
accelerating in the second half of 2021
Imricor FY20 Investor Presentation, February 2021View entire presentation